Arca
Skip to content

Alpha-1 antitrypsin deficiency (aatd)

Drug research and approvals for alpha-1 antitrypsin deficiency (aatd): what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 16, 2026, 23 studies of alpha-1 antitrypsin deficiency (aatd) are recruiting on ClinicalTrials.gov, Health Canada has authorized 8 drug trials for it since 2013, and FDA has 0 approved and 14 open orphan designations naming it.

  • Recruiting worldwide: 23
  • Trials authorized in Canada: 8
  • FDA orphan approvals: 0
  • EU medicines: 0

Recruiting Now

Newest start dates first, of 23 recruiting on ClinicalTrials.gov ↗

Trials Authorized in Canada

Newest first; search them all in Canada trials
Apr 25, 2024A phase 1b/2a open-label single ascending doses (sad) and multiple ascending doses (mad) research study to evaluate safety, tolerability, pharmacokinetics and…WVE-006WAVE LIFE SCIENCES UK LTDOngoing
Sep 18, 2023A phase 2, open-label study evaluating efficacy and safety of vx-864 in subjects with alpha-1 antitrypsin deficiency who have the pizz genotype, over 48 weeksVX-864Vertex PharmaceuticalsClosed
Jan 24, 2023A randomized, double-blind, placebo-controlled, phase 3 study to evaluate the efficacy and safety of fazirsiran in the treatment of alpha-1 antitrypsin…FAZIRSIRAN (TAK-999)Takeda Pharmaceuticals USAOngoing
Aug 5, 2020A phase 2, randomized, double-blind, placebo-controlled study of the efficacy and safety of vx-864 in pizz subjectsVX-864Vertex PharmaceuticalsClosed
Dec 27, 2019A phase 2, randomized, double-blind, placebo-controlled study of the efficacy and safety of vx-814 in pizz subjectsVX-814Vertex PharmaceuticalsClosed
Jul 31, 2019A placebo-controlled, multi-dose, phase 2/3 study to determine the safety, tolerability and effect on liver histologic parameters in response to aro-aat in…ARO-AAT (ADS-001)ARROWHEAD PHARMACEUTICALS, INC.Ongoing
Aug 22, 2018A phase 2, proof-of-concept, multicentre, double-blind, randomised, dose-ascending, sequential group, placebo-controlled study to evaluate the mechanistic…ALVELESTAT (MPH966)MEREO BIOPHARMA 4 LTDClosed
Jul 5, 2016An open-label, multi-dose, phase 2 study to determine the safety, tolerability and effect on circulating and intrahepatic alpha-1 antitrypsin levels of arc-aat…ARC-AATARROWHEAD PHARMACEUTICALS, INC.Ongoing

FDA Orphan Designations

Approved first, then open designations, newest first
Nov 19, 2025RNA editing antisense oligonucleotide (ASO)treatment of alpha-1 antitrypsin deficiency.”AIRNA CorporationDesignated
Nov 6, 2025in vivo target-primed reverse transcription genome editing…treatment of alpha-1 antitrypsin deficiency (AATD)Tessera Therapeutics, Inc.Designated
May 28, 2025a lipid nanoparticle-based therapy consisting of a guide…treatment of alpha-1 antitrypsin deficiencyBeam TherapeuticsDesignated
Apr 9, 2025lipid nanoparticles containing base editor CRISPR-Cas9…treatment of alpha-1 antitrypsin deficiencyYoltech Therapeutics Co., LtdDesignated
Mar 12, 2025RNA editing antisense oligonucleotide (ASO) KB100967…treatment of alpha-1 antitrypsin deficiency (AATD)Korro Bio, Inc.Designated
Dec 12, 2023oxoindoline carboxamide compoundTreatment of alpha-1 antitrypsin deficiencyBioMarin Pharmaceutical Inc.Designated
Sep 1, 2023A replication-defective, non-integrating herpes simplex…Treatment of Alpha-1 antitrypsin deficiencyKrystal Biotech, Inc.Designated
Mar 2, 2022IgG4 Fc linked recombinant human AAT (alpha-1 antitrypsin)Treatment of Congenital Alpha-1 Antitrypsin Deficiency (AATD)Sanofi Aventis US. LLC (A Sanofi Company)Designated
Oct 25, 2021AlvelestatTreatment of Alpha-1 Antitrypsin DeficiencyMereo Biopharma 4 LimitedDesignated
Oct 19, 2020CHO cell line produced human Alpha-1 Antitrypsin (CHO-AAT)…treatment of alpha-1 antitrypsin deficiencyCaravella Biopharma SADesignated
Feb 19, 2020Recombinant human alpha-1 antitrypsin from Oryza sativaTreatment of alpha-1 antitrypsin deficiencyWuhan Healthgen Biotechnology CorporationDesignated
Feb 14, 2018double stranded oligomer ADS-001 RNA interference-based…Treatment of alpha-1 antitrypsin deficiencyTakeda Development Center Americas, Inc.Designated
Mar 19, 2002hyaluronic acidTreatment of emphysema in patients due to alpha-1 antitrypsin deficiencyCoTherixDesignated
Mar 29, 1991Recombinant secretory leucocyte protease inhibitorTreatment of congenital alpha-1 antitrypsin deficiency.Amgen Inc.Designated

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.